Procter & Gamble chairman and CEO A.G. Lafley is generally a "sunny and upbeat" kind of guy himself, as
WWD's Molly Prior describes him. And what is he so sunny and upbeat
about? Well, for one thing, the fact that because things are so bad in the world of media and advertising, P&G "can just walk in and tear up the contract."
Though I
wouldn't classify Lafley as a meme agent for joy in Adland, there are, as always, lessons for other brand marketers here besides "carry the biggest stick." He told analysts in New York
yesterday that "brands matter most when every dollar counts." (He would say that, wouldn't he?) He also said that P&G "continues to tweak its portfolio to further maximize its
core capabilities and shift to higher margin businesses."
Included in that tweaking will be a halt in research and development investment for pharmaceutical products, David
Holthaus reports in the
Enquirer. It will focus instead on over-the-counter health products such as
heartburn medication Prilosec and Vicks cough and cold products, Lafley says. P&G will also end research investments in Intrinsa, its female testosterone patch awaiting Food and Drug
Administration approval, and in Asacol, a drug that treats ulcerative colitis.
advertisement
advertisement
Read the whole story at Women’s Wear Daily, Cincinnati Enquirer »